The race for coronavirus treatments and vaccines is expected to maintain its frenetic pace in June.
There's no shortage of activity in hunting for pharmaceutical solutions to COVID-19, the disease caused by the novel coronavirus. The World Health Organization has tallied 125 coronavirus vaccine programs. Several hundred experimental drugs are being looked at to treat infected people. Roughly 40 treatments are now in human testing, according to Informa Pharma Intelligence.
Separately, University of Minnesota researchers are set to soon publish their research from a trial testing whether hydroxychloroquine can protect people from the coronavirus. The malaria pills were given as a post-exposure prophylaxis treatment, meaning after someone had been exposed to the virus but before they had developed symptoms.
All of these vaccine candidates will start in small-scale studies primarily focused on safety. Researchers will also test volunteers to see if the vaccine provoke an immune response, although additional trials with more people will be needed to tell if any immune responses actually protect people from the virus. The German biotech CureVac with a messenger RNA vaccine
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »